The VACUETTE® Virus Stabilization Tube (VST) has been used millions of times around the world

Since the outbreak of the COVID-19 pandemic, virus detection has increasingly become the focus of healthcare attention.
The VACUETTE® Virus Stabilization Tube (VST) has been used millions of times worldwide for the safe transport of sample material for PCR testing in the laboratory. As a global player, Greiner Bio-One is close to its customers.

Successful Business Development in 2021
In 2021, Greiner Bio-One International GmbH generated sales of EUR 695 million (+ 0.4 %; FY 2020: EUR 693 million) with 2,540 employees, 28 branches and numerous distribution partners in more than 100 countries. Greiner Bio-One is part of Greiner AG, based in Kremsmünster (Austria).

As in 2020, the VACUETTE® Virus Stabilization Tube (VST) was largely responsible for the very positive sales development in the previous year. However, the positive business development in 2021 can also be explained by the increased demand for standard products in both the business areas Preanalytics as BioScienceThe products also play an important role in the diagnosis of SARS-CoV2 and the development of vaccines. BioScience products include: ELISA microplates, tissue culture tubes and -bottles and products for mass tissue culture.

Challenges tackled thanks to dedicated employees
As an internationally active company, Greiner Bio-One has been strongly affected by the overstrained and partially interrupted supply chains. Serious delays in international container deliveries and a huge increase in freight costs and raw material prices have had an impact on business operations. The fact that this very challenging situation has been successfully overcome is partly due to forward-looking planning, but above all to the high level of dedication of the employees. 

Setting the course for the future: greening and digitalization
In the area of greening, subprojects have been successfully completed. For example, the production sites in Austria and Germany have switched to certified green electricity. In total, the energy efficiency projects have saved 1,670 MWh of electricity. A trend that has been going on for some time and will become increasingly important in the future is the topic of digitalization in healthcare. Greiner Bio-One has developed a system solution that has been in use for several years and that will be further developed and distributed in a more targeted manner in the future via a new joint venture.

New slogan “making a difference” 
The company redefined its value proposition to customers in a large-scale project last year and wants to position itself more strongly in the future under the motto “making a difference” in the areas of technology, quality and sustainability as a global partner that implements customer requirements with efficiency and expertise. The aim is to build long-term partnerships based on trust.

Detailed information can be found here: https://reports.greiner.com/annual-report-2021/en/